Evaluating the anti-tumor potential of PARP inhibitor treatment in combination with dendritic cell-based therapies in triple negative breast cancer Vrije Universiteit Brussel
germline BRCA1/2 mutations can currently benefit from targeted therapy with PARP inhibitors (PARPi).
However, even these patients relapse and hence combination strategies with PARPi are being investigated in
patients with and without BRCA1/2 mutations. One strategy to increase the response to PARPi is to improve the ...